Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned an average recommendation of "Buy" from the eleven research firms that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $16.00.
Several equities analysts have weighed in on BCRX shares. Needham & Company LLC reiterated a "hold" rating on shares of BioCryst Pharmaceuticals in a report on Thursday, April 15th. Piper Sandler upped their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $18.00 and gave the stock an "overweight" rating in a report on Friday, May 28th. Barclays upped their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, May 7th. Cowen upped their price objective on shares of BioCryst Pharmaceuticals from $18.00 to $21.00 and gave the stock an "outperform" rating in a report on Thursday, June 17th. Finally, Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $16.00 to $20.00 in a report on Friday, May 7th.
NASDAQ BCRX traded up $0.14 during trading hours on Wednesday, hitting $16.94. 18,205 shares of the company's stock traded hands, compared to its average volume of 2,346,555. BioCryst Pharmaceuticals has a 52-week low of $3.30 and a 52-week high of $17.74. The company has a market cap of $3.01 billion, a P/E ratio of -14.00 and a beta of 2.62. The company's 50-day moving average is $15.99.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Thursday, May 6th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.10). The firm had revenue of $19.06 million during the quarter, compared to analyst estimates of $12.80 million. BioCryst Pharmaceuticals had a negative net margin of 653.70% and a negative return on equity of 5,272.40%. Analysts anticipate that BioCryst Pharmaceuticals will post -1.1 EPS for the current fiscal year.
In other BioCryst Pharmaceuticals news, Director George B. Abercrombie sold 5,000 shares of the stock in a transaction that occurred on Thursday, July 15th. The shares were sold at an average price of $15.69, for a total value of $78,450.00. Following the sale, the director now directly owns 8,000 shares of the company's stock, valued at approximately $125,520. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider William P. Sheridan sold 71,759 shares of the stock in a transaction that occurred on Thursday, May 27th. The shares were sold at an average price of $15.00, for a total transaction of $1,076,385.00. Following the completion of the sale, the insider now directly owns 39,434 shares in the company, valued at $591,510. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,426 shares of company stock worth $1,336,406. 4.80% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of BCRX. Artisan Partners Limited Partnership acquired a new stake in BioCryst Pharmaceuticals during the 1st quarter worth $30,770,000. Goldman Sachs Group Inc. increased its position in shares of BioCryst Pharmaceuticals by 614.9% during the first quarter. Goldman Sachs Group Inc. now owns 2,170,590 shares of the biotechnology company's stock worth $22,075,000 after purchasing an additional 1,866,955 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $7,740,000. Nuveen Asset Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 59.3% in the 1st quarter. Nuveen Asset Management LLC now owns 2,504,355 shares of the biotechnology company's stock valued at $25,469,000 after purchasing an additional 931,841 shares during the last quarter. Finally, FMR LLC boosted its position in shares of BioCryst Pharmaceuticals by 15.9% in the 1st quarter. FMR LLC now owns 3,467,998 shares of the biotechnology company's stock valued at $28,229,000 after purchasing an additional 475,989 shares during the period. 58.67% of the stock is currently owned by hedge funds and other institutional investors.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
See Also: Do stock splits help investors?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here